The global antigen skin test market was valued at around US$ 2,027.6 Million at the end of 2021. The market is projected to register a 5.2% CAGR and top a valuation of US$ 3,548.63 Million by 2032.
Changing lifestyles and environmental factors are contributing to an increase in allergy disorders prevalence worldwide, as antigen skin tests are the most effective diagnostic method for identifying allergies, this is anticipated to increase demand for them.
Antigen skin testing is a diagnostic technique used to determine the cellular immune capability. The immune systems are mostly being tested against the antigens. The primary indication for an antigen skin test is the detection of immediate or delayed hypersensitivity to endogenous or foreign antigens. Antigen is injected with a needle into the top layer of skin during the antigen skin test technique. Usually on the forearm, a very small amount is injected. An injection site lump that signals the presence of an antigen and the injection site are labelled.
Skin at the injection site will become red as the immune system begins to respond as a result of the antigen. The capability of the immune system depends on the level of hypersensitivity. To prevent negative results from other hypersensitivity reactions, such as those from a tuberculosis test, the antigen skin test is used. With viral, fungal, and bacterial antigens to which a healthy person is sensitive, antigen skin testing can evaluate a delayed or cellular kind of hypersensitivity reaction. Antigen exposure is proven by a positive antigen skin test. The lymphocytes and immunoglobulins are the main causes of the inflammatory reactions at the antigen skin test site.
| Attributes | Details |
|---|---|
| Antigen Skin Test Market Value in 2021 | US$ 2,027.6 Million |
| Antigen Skin Test Market Value in 2032 | US$ 3,548.63 Million |
| Antigen Skin Test Market CAGR (2022 to 2032) | 5.22% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Companies in the antigen skin test market have recently invested heavily in the development of novel tests in order to take advantage of the untapped market's prospects. Hospital-based laboratories are under pressure to provide more services at a lower cost as a result of healthcare cost containment in the majority of developed markets.
Additionally, the prevalence of chronic diseases is increasing, and healthcare facilities are dealing with an ageing population. In accordance with this, antigen skin test producers can seize the chance to offer supplementary services and assistance. All of these elements contribute to the market for antigen skin tests expanding rapidly.
Moreover, with technical improvements, antigen detection methods are changing, which is assisting in a more precise diagnosis of allergies. This is accelerating the global market for antigen skin tests.
The antigen skin test market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
North America has dominated the regional antigen skin test market due to its well-established healthcare system. Additionally, due to the widespread use of antigen skin tests, the USA in particular is dominant in North America.
Moreover, the Asia Pacific is anticipated to have profitable growth throughout the forecast period, due to the increased incidence of infectious diseases and expanding government efforts to upgrade public health infrastructure in the region. Additionally, the demand for medical products and services has increased as a result of economic growth and a rise in living standards, which will help the market grow throughout the projection period.
Principal Consultant
Becton, Dickinson and Company (BD), Coris Bioconcept, Nielsen BioSciences Inc., Physicians Total Care Inc., Sanofi Pasteur Limited, Allermed Laboratories, Inc, Par Pharmaceuticals, Era Biology Co. Ltd, ELITech Group, and QIAGEN
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 5.2% 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Million, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segment Covered | Test Type, End-User |
| Region Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Argentina, Germany, United Kingdom, France, Spain, Italy, Russia, China, Japan, South Korea, India, Malaysia, Indonesia, Thailand, Australia, New Zealand, GCC Countries, South Africa, North Africa, Turkey |
| Key Players | Becton, Dickinson and Company (BD); Coris Bioconcept; Nielsen BioSciences Inc.; Physicians Total Care Inc.; Sanofi Pasteur Limited; Allermed Laboratories, Inc; Par Pharmaceuticals; Era Biology Co. Ltd; ELITech Group; QIAGEN |
| Customization | Available Upon Request |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global antigen skin test market is anticipated to register a CAGR of 5.2% during the forecast period.
Becton, Dickinson and Company (BD), Coris Bioconcept, Nielsen BioSciences Inc., Physicians Total Care Inc., Sanofi Pasteur Limited, Allermed Laboratories, Inc, Par Pharmaceuticals, Era Biology Co. Ltd, ELITech Group, and QIAGEN, among others are some prominent antigen skin test market players.
Explore Healthcare Insights
View Reports
Antigen Skin Test Market
